Related Experiment Video

Updated: Oct 29, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.6K

CD38-Directed Therapies for Management of Multiple Myeloma

Hamza Hashmi1, Muhammad Husnain2, Ali Khan3

  • 1Department of Medicine, Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, USA.

Immunotargets and Therapy
|July 8, 2021
PubMed

Insights

Survival for multiple myeloma has greatly improved due to new treatments. CD38-targeted antibody therapies, like daratumumab, show high effectiveness in newly diagnosed and relapsed multiple myeloma patients.

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Multiple myeloma survival has significantly improved over the last 20 years.
  • Novel therapies including immunomodulatory agents, proteasome inhibitors, stem cell transplant, and monoclonal antibodies have driven these advances.
  • CD38-targeted antibody therapies represent a key advancement in treatment strategies.

Purpose of the Study:

  • To summarize recent clinical data on CD38-directed therapies for multiple myeloma.
  • To review current and emerging antibody-based treatments targeting the CD38 surface marker.
  • To highlight the efficacy of these therapies in various multiple myeloma settings.

Main Methods:

  • Review of recent clinical trial data and scientific literature.
  • Analysis of efficacy and safety data for CD38-targeted agents.
  • Focus on therapies including daratumumab and isatuximab.

Main Results:

  • CD38-targeted therapies, such as daratumumab and isatuximab, are highly effective.
  • These agents demonstrate significant efficacy as monotherapy and in combination regimens.
  • Positive outcomes are observed in both newly diagnosed and relapsed multiple myeloma cases.

Conclusions:

  • CD38-directed therapies have become integral to multiple myeloma treatment.
  • Current and emerging CD38-targeted agents offer substantial therapeutic benefits.
  • These antibody-based treatments continue to improve survival outcomes in multiple myeloma.
Keywords:
CD38antibody drug conjugatebispecific antibodydaratumumabisatuximabmultiple myeloma

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.2K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
781
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
268
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
294